News & Events
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
READ MORECrinetics Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Event Date: December 18, 2023
READ MORECrinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational...
READ MORECrinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new...
READ MORECrinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
Crinetics management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference on November 28 and the...
READ MORE6th Annual Evercore ISI HealthCONx Conference
Event Date: November 28, 2023
READ MORECrinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to four new...
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2023 progress
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
